Clinical Trial Update: Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis [Phase 4]

View source ↗

Summary

Phase 4 clinical trial investigating dupilumab's effect on the host-microbe interface in atopic dermatitis was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Dupilumab (dupilumab)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Atopic Dermatitis (AD) | Phase 4 | Status: TERMINATED | Results posted: 2021-06-14